High Prevalence of Depressive Symptoms in Patients With Type 1 and Type 2 Diabetes in Developing Countries: Results From the International Diabetes Management Practices Study
posted on 2021-05-07, 21:46authored byPablo Aschner, Juan José Gagliardino, Hasan Ilkova, Fernando Lavalle, Ambady Ramachandran, Jean Claude Mbanya, Marina Shestakova, Yann Bourhis, Jean-Marc Chantelot, Juliana C.N. Chan
<b>Objective</b>
<p>Depression is common in people with
diabetes but data from developing countries are scarce. We evaluated the prevalence
and risk factors for depressive symptoms in patients with diabetes using data from
the International Diabetes Management Practices Study (IDMPS).</p>
<p><b>Research Design and Methods</b></p>
<p>IDMPS is an ongoing multinational,
cross-sectional study investigating quality of care in patients with diabetes
in real-world settings. Data from wave 5 (2011), including 21 countries, were
analyzed using the Patient Health Questionnaire (PHQ)-9 to evaluate depressive
symptoms. Logistic regression analyses were conducted to identify risk factors
of depressive symptoms.</p>
<p><b>Results</b></p>
<p>Of 9865 patients eligible for
analysis, 2280 had type 1 and 7585 had type 2 diabetes (treatment: oral glucose
lowering drugs [OGLD] only, n=4729; OGLDs plus insulin, n=1892; insulin only,
n=964). Depressive symptoms (PHQ-9 score ≥5) were reported in 30.7% of those
with type 1 diabetes. In patients with type 2 diabetes, the respective figures
were 29.0% for OGLDs only, 36.6% for OGLDs plus insulin, and 46.7% for insulin only
subgroups. Moderate depressive symptoms (PHQ-9 score 10–19) were observed in 8–16%
of patients with type 1 or type 2 diabetes. Female sex, complications, and low
socioeconomic status were independently associated with depressive symptoms.<a> In type 1 and type 2 diabetes OGLDs only groups,
depression was associated with poor glycemic control.</a></p>
<p><b>Conclusions</b></p>
<p>Depressive symptoms are common in patients
with diabetes from developing countries calling for routine screening,
especially in high-risk groups, to reduce the double burden of diabetes and
depression and their negative interaction.</p>
Funding
The study was funded by Sanofi. Support with editing the manuscript was provided by Fishawack Communications Ltd, UK, a Fishawack Health company, funded by Sanofi.